SPTX
NASDAQSeaport Therapeutics Inc.
Seaport Therapeutics Inc. (SPTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for SPTX, including 2 SEC filings, 1 earnings update and 1 insider trade. The most recent was published Nov 4, 2026.
SPTX rankings
News · 26 weeks4+100%
2026-05-102026-11-01
Mix490d
- SEC Filings2(50%)
- Earnings1(25%)
- Insider1(25%)
Activity · 52 weeks42 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
4 items- INSIDERDirector Torres Denice bought $99,325 worth of shares (5,000 units at $19.86) (SEC Form 4)4 - Seaport Therapeutics, Inc. (0002042347) (Issuer)
- SECSEC Form 10-Q filed by Seaport Therapeutics Inc.10-Q - Seaport Therapeutics, Inc. (0002042347) (Filer)
- SECSeaport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Seaport Therapeutics, Inc. (0002042347) (Filer)
- PRSeaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressAnnounced positive topline data from Phase 1 driving simulation trial of GlyphAllo™, showing that GlyphAllo did not impair next-morning driving performance compared to placebo Dosed first patient in Phase 2a trial of GlyphAgo™ in patients with generalized anxiety disorder (GAD) and sleep disturbance; Company expects to initiate Phase 2/3 trial of GlyphAgo in patients with GAD in 1H 2027 Enrollment in Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Cash, cash equivalents, and investments of $403.8 million as of September 30, 2026, expected to fund operations into 2029 through three mid-to-late-stage data readouts
SPTX FAQ
7 questionsWhat does Seaport Therapeutics Inc. do?
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph platform to overcome those limitations and invent innovative oral therapies. With an experienced team of...What is the latest news on SPTX?
In the last 30 days Quantisnow tracked 4 wire items for SPTX: 2 SEC filings, 1 earnings update and 1 insider trade. The most recent was published on November 4, 2026.Where does SPTX stock trade?
Seaport Therapeutics Inc. (SPTX) is listed on NASDAQ.What sector and industry is SPTX in?
Seaport Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Seaport Therapeutics Inc. go public?
Seaport Therapeutics Inc. (SPTX) completed its IPO in 2026.What companies are similar to SPTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPTX side-by-side with any of them on Quantisnow.How can I track SPTX on Quantisnow?
Quantisnow aggregates Seaport Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPTX to receive live email and push alerts on every new disclosure.